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Abstract  
Background  
Most post-colonoscopy interval colorectal cancers are proximal. Serrated polyps are often pre-
cursors to these and considered hard to detect. We assessed the safety, feasibility and economic 
impact of chromocolonoscopy on detection of proximal serrated neoplasia.  
Methods  
A parallel group randomised controlled, open label multicentre trial (ClinicalTrials.gov: 
NCT01972451) within Bowel Screening Wales (BSW). Participants positive for Faecal Occult 
Blood were randomised 1:1 (using minimisation stratified by centre with an 80:20 random 
element) to either standard white light colonoscopy or chromocolonoscopy (indigo carmine 
dye (0·2%)) using a secure, internet-based, computerised, randomisation system that used 
centralised, dynamic allocation. Participants were followed up for one year and data from index 
colonoscopies and associated clearance procedures were analysed. All proximal polyps were 
reviewed by an expert pathologist panel. The study was powered to see whether or not the extra 
procedure time taken to conduct chromocolonoscopy was acceptable (a non-inferiority design 
with an inferiority margin of 15 minutes) using a per protocol analysis.  
Findings  
Between November 2014 - June 2016, 741 of 1031 were eligible and consented, 360 were 
randomized to white light colonoscopy and 381 to chromocolonoscopy. In the 
chromocolonoscopy arm, the procedure took an average of 6·3 (95% CIs: 4·2-8·4) minutes 
longer (well within the pre-specified inferiority margin of 15 minutes) but serious adverse 
reaction rates (two in the standard and four in the chromocolonoscopy arm with five of these 
being incidences of post polypectomy bleeding and one case of anxiety and hyperventilation), 
colonoscopy quality measures, comfort scores and sedation were similar in each arm. The 
proximal serrated polyp detection rate was significantly higher in the chromocolonoscopy arm 
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(45/381 (11·8%) vs 23/360 (6·4%); multivariable OR 2·04, 95% CI: 1·18-3.50, p=0·010). An 
additional investment of £81 (95% CI: £69.91- £92.09) per procedure is required to introduce 
chromocolonoscopy into routine practice.  
 
Interpretation  
Chromocolonoscopy is feasible within a population based colorectal cancer screening 
programme, safe and significantly increased detection of proximal serrated neoplasia and other 
polyp types. Larger RCTs of chromocolonoscopy powered for improved detection of 
significant serrated polyps and for longer term follow up to investigate the impact on reduction 
of interval cancers within screening populations are warranted.  
Funding 
Health and Care Research Wales (RfPPB –1021) 
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Research in context  
Evidence before this study  
A systematic review of chromoscopy versus conventional endoscopy for the detection of 
polyps in the colon and rectum was published in the Cochrane Database of Systematic Reviews 
in 2016. To capture randomised trial evidence published since then, on 7 December 2018, we 
searched Ovid MEDLINE using: ((randomised or randomized).ab. or trial.ti. or "Clinical 
trial".pt. or (exp Randomized Controlled Trials as Topic/ or randomised).mp.) and ("enhanced 
colonoscopy" or chromoscopy or chromocolonoscopy or panchromoendoscopy or 
chromoendoscopy or "pan-chromoscopy" or panchromoscopy).mp. and 2014:2018.(sa_year). 
Titles and abstracts of 58 records were screened, and articles on narrow spectrum 
light/magnifying chromoendoscopy/electronic imaging/narrow band imaging/virtual 
chromoendoscopy/buscopan/side optic-enhancement/polypectomy technique interventions 
and gastric/oesophageal/Inflammatory Bowel Disease/Lynch syndrome cohorts were excluded 
leaving 4 studies. Of these, one was a review, one was a trial in patients with serrated polyposis 
syndrome only, one was a trial of the safety of oral methylene blue in 10 patients only, and one 
looked at the classification rather than detection of polyps.    
 
Missed proximal serrated neoplasia may contribute to post-colonoscopy colorectal cancer. 
Chromocolonoscopy has been investigated in different settings and shown to increase adenoma 
detection rates. However, its use in the detection of proximal serrated polyps and implications 
for screening programmes and PCCRC has not been assessed.   
 
Added value of this study  
It is feasible to implement dye enhanced colonoscopy in a population based colorectal cancer 
screening program with an average 6·3 minutes of additional time taken per procedure. We 
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found more polyps of all types including significantly more proximal significant serrated 
lesions in the chromocolonoscopy group. An additional investment of £81 (95%CI: £69.9-
£92.09) per procedure is required to introduce chromocolonoscopy into routine practice.   
 
Implications of all the available evidence  
This is the first study to demonstrate that, with rigorous trial design incorporating high quality 
standardised colonoscopy, chromocolonoscopy can be implemented within a population 
colorectal cancer screening programme with estimation of additional time and cost associated 
with it. It is the largest RCT of chromocolonoscopy in the detection of proximal serrated 
neoplasia and provides a screening population estimate of yield with minimisation of bias due 
to colonoscopist or pathology related factors. Further larger trials of chromocolonoscopy are 
warranted to look for a difference in proximal significant serrated lesion detection with full 
economic evaluation of follow up to assess clinical effectiveness over time and impact on 
clinical practice for surveillance. 
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Introduction 
 
Screening has been shown to reduce colorectal cancer (CRC) incidence and mortality.1 Studies 
suggest that this benefit is substantial in the reduction of distal colorectal cancers but modest 
for proximal colorectal cancers.2,3 Additionally, most cancers developing after an index 
colonoscopy, i.e. interval cancers or post-colonoscopy CRCs (PCCRCs), are located 
proximally.4 Studies have reported that interval CRC within 3 years after colonoscopy account 
for 3.4% to 9% of all CRCs and their incidence is associated with colonoscopy quality 
measures5,6 therefore individuals may be falsely reassured by screening. Two types of factors 
may contribute to the occurrence of proximal interval CRCs: technical (operator/procedure) 
dependant factors which can result in missed lesions, lower detection rates, and incomplete 
resection of lesions,7 and polyp biology dependent factors5,8 which relate to the difficulty in 
detection due to morphology, potential accelerated rate of growth, and molecular 
characteristics.9,10  
 
Apart from the traditional adenoma to carcinoma pathway, it has been recognised that subsets 
of serrated lesions (SLs) cause cancer via an alternative pathway (serrated neoplasia 
pathway).11 This may be responsible for up to 20% of all sporadic CRCs.12 Several studies have 
also demonstrated that SLs are common precursors to proximal interval cancers.10 These polyps 
are flat or non-polypoid in morphology making them more difficult to detect endoscopically 
and studies show wide variation in detection rates (1-20%) amongst endoscopists.13,14 There 
also remains considerable variability in histopathological interpretation of serrated polyp 
subtypes affecting the accurate categorisation of potential precursors to the serrated 
pathway.15,16 This is further compounded by the existence of two different definitions of sessile 
serrated lesions (SSLs) promoted by the WHO17 (World Health Organisation) and the AGA18 
(American Gastroenterological Association) and estimated prevalence rates vary according to 
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the criteria used.19,20  
 
Pan-colonic chromocolonoscopy already forms part of standard practice in surveillance in 
high-risk cases of inflammatory bowel disease and is part of national and international 
guidelines.21 Chromocolonoscopy has been investigated in different settings and shown to 
increase adenoma detection rates.22 However, its use in the detection of proximal serrated 
polyps and implications for screening programmes and PCCRC has not been assessed. 
Technical factors affecting polyp and cancer detection rates include quality of bowel 
preparation, training and experience of the colonoscopist, and various procedural techniques.23 
Colonoscopists in the UK undergo a rigorous standardised assessment and accreditation 
process in order to achieve high quality minimum standard criteria (e.g. adenoma detection 
rates, withdrawal times, comfort scores) that are monitored regularly making a UK CRC 
screening programme the appropriate setting to investigate chromocolonoscopy.  
 
The aims of this study were to assess: feasibility of implementation within a population wide 
screening programme and of recruitment to a larger definitive trial, whether 
chromocolonoscopy takes an acceptable length of additional time to conduct and the associated 
costs, and the proximal serrated polyp detection rates (with standardised and monitored 
operator and procedure quality and rigorous histopathology assessment) in the trial arms to 
inform the sample size of a future trial. 
 
Methods 
Study design and participants 
This was a multicentre, randomized, open-label, feasibility trial of dye-enhanced 
chromocolonoscopy vs standard white light colonoscopy. All Bowel Screening Wales (BSW) 
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centres were encouraged to participate in the trial. All members of the public (aged between 60 
and 74 years) testing positive on Faecal Occult Blood Testing (FOBT) in the BSW programme 
who were eligible for an index screening colonoscopy (i.e. this excluded Polyposis syndromes, 
Lynch syndrome and those under regular colonoscopic surveillance for chronic inflammatory 
bowel disease) were assessed for trial eligibility by Specialist Screening Practitioners during 
telephone assessment clinics to discuss their colonoscopy. People who had undergone previous 
colorectal surgery, or with known allergy to food colouring agents, were excluded. Eligible 
people had the study described to them and, if they were interested in participating, were sent 
more information (including a participant information sheet and consent form) along with 
standard information about the screening colonoscopy. Informed consent was taken by a 
Specialist Screening Practitioner when the patient attended for colonoscopy, prior to the patient 
being told which trial arm they had been allocated to.   
 
Randomisation and masking 
All potential participants were randomised 1:1 (using minimisation stratified by centre with an 
80:20 random element) to either standard or chromocolonoscopy for their index procedure 
using a secure, internet-based, computerised, randomisation system that used centralised, 
dynamic allocation. It was not possible to blind either the patient or colonoscopist to trial arm 
but we did blind the expert panel of three GI pathologists (see below) who classified every 
proximal polyp.    
 
Procedures 
Participants randomised to white light colonoscopy had a colonoscopy conducted as per 
standard practice. For participants randomised to the chromocolonoscopy arm, once the 
caecum was reached, indigo carmine dye (0·2% as used in standard clinical practice; 
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manufactured by Diagmed (UK)) was sprayed on the surface of the proximal colon (caecum to 
splenic flexure) using a pump assisted spray through the colonoscope on withdrawal. This 
required specific training to all the colonoscopists and Specialist Screening Practitioners to 
ensure standardisation of technique of dye dilution and spray as well as detection, identification 
and removal of polyps under indigo carmine dye. We were aware that the colonoscopists 
undertaking screening in this cohort were all accredited to the same standard though some had 
previous experience of pan-colonic dye spray use in the context of chronic inflammatory bowel 
disease and Lynch syndrome whereas others did not. We ensured that all participating 
colonoscopists attended a day long training event including quizzes of images and video prior 
to and after the training, a training resource for reference, as well as lectures and video tutorials 
on technique and lesion detection with and without indigo carmine dye spray. We also included 
training on the PARIS classification, Kudo classification and lesion characterisation with 
virtual and dye based chromocolonoscopy. In participants allocated to this arm with inadequate 
bowel preparation on the day, dye was used at the subsequent adequately prepared 
colonoscopy, otherwise repeat procedures used standard white light colonoscopy. 
Colonoscopists were allowed to use the irrigation pump with water for washing colonic mucosa 
without any restriction in both trial arms. Ten sites used high-definition colonoscopes (not 
mandated), one high-resolution colonoscopes and one standard definition colonoscopes. All 
adverse events were reported until 30 days post-colonoscopy.  
 
Polyps retrieved from all index colonoscopies and at associated clearance procedures up to one 
year after were included in the analysis. Surveillance procedures were not included. Polyps 
found on computed tomographic colonography (CTC) undertaken for incomplete procedures, 
were excluded from the analysis.  
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Outcomes  
The primary endpoint was time taken to perform the colonoscopy procedure defined as from 
the time when the scope was inserted to withdrawal from the anus. This, together with the data 
on colonoscopy outcomes, polyps found, bowel preparation, sedation, and technical quality 
indicators was collected by Specialist Screening Practitioners as part of routine data collection. 
Data on aspirin use, smoking, family history of bowel cancer, endoscopist assessment of 
procedural difficulty, the data in Supplementary Table S1, and data on resource use during 
index colonoscopy (probes, coagraspers, clips, snares, pots, etc) were not rountinely collected 
and had to be collected on a trial specific case report. 
 
All proximal (defined as at or above the splenic flexure) polyps included in the analysis, 
regardless of initial reported histology, were collected from local centres for central review by 
an expert panel of three GI consultant pathologists. All three were part of the national referral 
pathways for the bowel cancer screening programme reviews of pathology and have 
involvement in pathologist training and accreditation as well as regular review of “second 
opinion” lesions as part of a national pathology expert panel. Pre-defined standard diagnostic 
criteria were agreed to avoid variation in final reports and were based on the WHO 
classification,17 though serrated lesions were also categorised according to AGA criteria.18 In 
accordance with UK guidance,24 the term ‘sessile serrated lesion’ (SSL) was used for lesions 
described elsewhere as ‘sessile serrated adenoma/polyp’ (SSA/P). The expert panel reviewed 
all slides independently and were blinded to the original report. Cases without diagnostic 
agreement were re-reviewed by all three pathologists to reach a consensus diagnosis. If this 
was not achieved, the lesion was deemed “unclassifiable”. 
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An ‘advanced adenoma’ was defined as a conventional adenoma with either high grade 
dysplasia (HGD), >25% villous histology, or measuring ≥10mm in size.17 ‘Serrated lesions’ 
(SLs) incorporated hyperplastic polyps, SSLs and traditional serrated adenomas (TSAs).  
‘Significant SLs’ incorporated SSLs with dysplasia, SSLs measuring ≥10mm and all TSAs. 
The term ‘advanced neoplasia’ incorporated all advanced adenomas and all significant SLs. 
 
A cost consequence analysis evaluates the costs associated with the colonoscopy procedures 
within the study to compare resource utilisation. The costs were assessed from the perspective 
of the UK NHS. Assessed in two parts, the additional costs of providing new resources required 
to implement chromocolonoscopy and resources used during routine practice. Implementation 
costs of chromocolonosopy included additional resources in the form of staff time (both 
“trainee” and “trainer”) to train in the new procedure and the cost of the contrast dye and 
dispersion equipment. Resource use data regarding staff time performing the procedure and 
medications/bowel preparation administered during a procedure were collected from all 
participating screening sites. Resources classified as consumables were only collected from 
one site during index colonoscopies. Details of resource use analysis methodology can be found 
in the Appendix 2 of the web appendix (pages 7-12).  
 
Statistical analysis 
This feasibility study was powered to look for non-inferiority of time taken to perform the 
colonoscopy procedure. Experience suggested that chromocolonoscopy may take 12 minutes 
longer but should be no more than 15 minutes longer than standard. Assuming a common 
standard deviation of 15 minutes (normally distributed based on BSW data), this required 858 
patients (power 90%, alpha=0·05 (one sided)) based on a two-group t-test. The protocol 
initially aimed to recruit 1052 patients to allow for ~18% loss to follow up for any reason. 
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However, the Trial Management Group decided to stop recruitment once 741 participants had 
been consented for the following reasons: 
i) set up of some centres took longer than anticipated 
ii) there was no loss to follow up after consent 
iii) 741 patients still gave 86% power. 
 
Data were analysed according to a pre-specified analysis plan using the Stata SE 14 statistical 
package except where indicated as post hoc in the results section. All analyses were by 
intention-to-treat except the analyses of colonoscopy performance (including the primary 
endpoint of procedure time) and technical quality indicators (Table 2 and Supplementary Table 
S1) which were only in those participants who had adequate bowel preparation at the index or 
a subsequent procedure as this is when dye was administered. The primary endpoint was 
assessed by calculating the 95% confidence intervals around the mean difference and 
comparing them to the non-inferiority margin. Proportions were compared using chi square 
tests. For detection rates, univariable logistic regression was used to calculate odds ratios for 
the trial arm effect as well as important prognostic variables (smoking, obesity, sex, family 
history of cancer). Multivariable models included all these variables, as well as screening centre 
as a random effect, using multilevel mixed-effects logistic regression. Aspirin data was only 
collected after the first 210 patients had been recruited and this was included in the models in 
sensitivity analyses. Patients found to have cancer also had polyps removed if found and we 
included these patients in the analyses of polyp detection rates. 
 
The analysis of the economic data was conducted on procedures with a complete set of original 
data across all resource use variables and on all available cases with mean imputation for sites 
that did not collect data on consumables. This allowed an overall resource use comparative cost 
14 
 
to be calculated for all patient procedures in the available cases analysis. T-tests was used to 
evaluate differences in resource use costs between the two trial arms. The cost-consequence 
analysis provides an indication of the additional costs associated with introducing 
chromocolonoscopy into routine practice.  
 
The trial protocol (ClinicalTrials.gov: NCT01972451) was approved by a UK Multi-Centre 
Research Ethics Committee (ref: 14/WA/0004) and was sponsored by Cardiff University. 
 
Role of the funding source 
Neither the funder nor the Sponsor of the study had any role in study design, data collection, 
data analysis, data interpretation, or writing of the report. CH, RR, and CP had full access to 
the raw data. SD had final responsibility for the decision to submit for publication.  
 
Results 
Patients 
Between 20 November 2014 and 16 June 2016, 1031 people testing positive on FOBT, and 
expected to proceed to colonoscopy after discussion with a Specialist Screening Practitioner, 
were assessed for eligibility from 12 out of 14 centres in the BSW screening programme with 
20 out of 23 colonoscopists recruiting participants (Figure 1). 903 of the 1031 people assessed 
were considered eligible for the trial and of these 741 (82%) consented.  Consent rates after 
randomisation were similar in each arm: 360/416 (87%) and 381/424 (90%) with standard and 
chromocolonoscopy respectively. Baseline characteristics were well balanced between trial 
arms (Table 1). Follow up of polyps collected at later polyp clearance procedures continued 
until 1 year after the last participant had their index procedure. 
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Procedures 
Participants in the chromocolonoscopy arm had more procedures (477 vs 427) than in the 
standard arm (Table 2).  This was due to more repeats to remove polyps or check completeness 
of previous excisions in line with current guidelines. In the chromocolonoscopy arm, more 
participants had a final outcome of high risk (12 month) surveillance (76/381 (19·9%) vs 
48/360 (13·3%); post hoc χ2=5·812, p=0·016) and fewer participants had an outcome of 
discharge back to routine FOBT testing (159/381 (41·7%) vs 162/360 (45·0%)).  
 
In the first (index) colonoscopy with adequate bowel preparation, the procedure time was 
longer in the chromocolonoscopy arm (mean 36·8 vs 30·6 minutes) (Table 2). However, the 
difference did not exceed the 15 minutes specified a priori as the non-inferiority margin (mean 
difference 6·3 minutes, 95% CIs: 4·2-8·4). The data showed some evidence of positive skew, 
but bootstrapping produced the same estimate for the confidence interval. The magnitude of 
this difference was reflected in the withdrawal times (mean 24·1 vs 18·7 minutes). The 
difference in procedure times was smaller when no polyps were removed (mean 28·6 vs 24·2 
minutes) compared to when polyps were removed (mean 41·3 vs 35·2 minutes). The bowel 
preparation scores, completion rates, endoscopist assessment of procedural difficulties, and 
procedure comfort scores were similar in each arm (Table 2). 
 
Technical quality indicators, percentage of participants who had a position change and other 
manoeuvres during the procedure, and use of antispasmodic and sedation at first colonoscopy 
were well balanced between trial arms (Supplementary Table S1 in web appendix p1). The 
mean volume of fluid sprayed (diluted dye 0.2%) in the chromocolonoscopy arm was 165.8ml 
(SD=62.3).  
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Adverse events 
Six Serious Adverse Reactions (SARs) were reported in the trial, two in the standard arm and 
four in the chromocolonoscopy arm of the trial with five of these being incidences of post 
polypectomy bleeding and one case of anxiety and hyperventilation). The rates of post-
polypectomy bleeding were: 1/358 (0·3%) vs 2/378 (0·5%) in the standard and 
chromocolonoscopy arms respectively. None of these cases required any further interventional 
procedures related to the bleeding. There were no allergic reactions or deaths.  
 
Polyps 
Figure 2 and Table 3 show the cancers detected and WHO classification of all polyps retrieved 
at index colonoscopy and associated clearance procedures up to one year afterwards. All but 
five proximal polyps were reviewed centrally by the expert panel. More polyps overall (903 vs 
570), and more polyps of each type were found in the chromocolonoscopy arm. No patients 
had serrated polyposis as defined by WHO criteria though it is likely that some cases may fulfil 
these criteria at subsequent colonoscopy.  
 
Detection rates for proximal SLs were significantly higher in the chromocolonoscopy arm with 
both univariable and multivariable analyses: 45/381 (11·8%); vs 23/360 (6·4%) univariable 
OR 1·96, 95% CI: 1·16-3·32, p=0·012; multivariable OR 2·04, 95% CI: 1·18-3·50, p=0·010) 
(Supplementary Table 2a in web appendix p2). A sensitivity analysis was conducted in the 
subset of patients with aspirin data (n=521) and the trial arm effect in the multivariable 
regression was still found to be significant (OR 1·98, 95% CI: 1·05-3·74, p=0·036), but the 
effect of currently taking aspirin was not (OR 1·79 in favour of taking aspirin, 95% CI: 0·72-
4·50, p=0·21). We also found a significantly higher detection rate in the chromocolonoscopy 
arm for SLs found anywhere in the colon: 81/381 (21·3%) vs 51/360 (14·2%), multivariable 
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OR 1·66, 95% CI: 1·12-2·46, p=0·012. SLs were more common in smokers (multivariable OR 
1·79, 95% CI: 1·00-3·22, p=0·050 for proximal SLs and multivariable OR 1·58, 95% CI: 1·03-
2·42, p=0·038 for all SLs). 
 
Secondary regression analyses compared other rates of polyp detection. While absolute polyp 
numbers are small there is a suggestion that detection rates of “significant” SLs anywhere in 
the colon were higher in the chromocolonoscopy arm (Supplementary Table 2b in web 
appendix p2) (multivariable OR 2·18, 95% CI: 0·88-5·37, p=0·092) and alsoc in males 
(multivariable OR 3·23, 95% CI: 0·94-11·2, p=0·063). Histological criteria for distinguishing 
hyperplastic polyps from SSLs differ between the WHO and AGA definitions of SLs. For a 
diagnosis of SSL the WHO recommendations17 require two or three contiguous crypts showing 
characteristic SSL-type appearances whilst the AGA proposals18 require only one such crypt. 
Accordingly, when the AGA definition of SSL was used, 13 proximal hyperplastic polyps were 
re-classified as SSLs (one ≥10mm in the chromocolonoscopy arm). This marginally increased 
the detection rate of “significant” SLs in the chromocolonoscopy arm: 17/381 (4·5%) vs 7/360 
(1·9%); multivariable OR: 2·31, 95% CI: 0·94-5·67, p=0·066). The detection rate of proximal 
SSLs was significantly higher in the chromocolonoscopy arm (Supplementary Table 2c in web 
appendix p3) (multivariable OR 1·91, 95% CI: 1·02-3·59, p=0·045), but this difference 
disappeared when the AGA definition of SSL was used: 34/381 (8·9%) vs 22/360 (6·1%), 
multivariable OR 1·58, 95% CI: 0·90-2·78, p=0·11. Higher adenoma detection rates were 
found in the chromocolonoscopy arm (60·9% vs 56·4% in Table 3). Analyses of advanced 
neoplasm detection rates suggest that obesity and male gender may be important risk factors 
(Supplementary Table 2d in web appendix page 3). A further multivariable analysis (data not 
shown) of advanced neoplasm detection rates conducted in the subset of patients with aspirin 
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data (n=521) in both arms of the trial combined found a significant protective effect of aspirin 
(23/103 (22·3%) vs 153/418 (36·6%), OR 2·11 95% CI: 1·27-3·51, p=0·004). 
 
Of the 85 SSLs (24 in standard and 61 in chromocolonoscopy arm) identified in both arms of 
the study combined, six of the ten (60·0%) with dysplasia were ≥10mm compared with only 
13 of the 75 (17·3%) without dysplasia (χ2=9·25, p=0·007). Surprisingly, none of the four 
proximal SSLs with dysplasia was ≥10mm while all six distal SSLs with dysplasia were 
≥10mm. 
 
Univariable logistic regression analysis identified statistically significant associations between 
the finding of any SSL and the presence of synchronous advanced adenoma(s) (OR 2·42, 95% 
CI: 1·19-4·93, p=0·015) and between any proximal “significant” SL and advanced adenoma(s) 
(OR 4·10, 95% CI: 1·01-16·7, p=0·049) in the chromocolonoscopy arm but not in the standard 
arm (Supplementary table S3 in web appendix p4).   
 
Economic evaluation  
The economic evaluation case analysis included 899 procedures (904 index and associated non-
surveillance repeat procedures conducted within one year (Table 2) minus five procedures (four 
from the chromocolonoscopy arm and one from the standard arm) with  missing data). 183 
(20%) of these (91 standard arm and 92 chromocolonoscopy arm) were first procedures 
conducted at the site that documented the use of consumables constituted the complete case 
analysis. Mean training cost per procedure was £4·94 and mean equipment cost £47·99 (a total 
implementation cost per procedure of £52·93). A spray catheter attached to the pump was used 
in only 30% of procedures with a higher cost of £40 per colonoscopy. This compared to the 
technique used in 70% of procedures of adapting existing pumps with tubing and a valve which 
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added £8·88 to the cost of the colonoscopy. Supplementary Tables S4 to S6 (web appendix p5-
6) show the higher costs associated with chromocolonoscopy. This is primarily due to the extra 
time required by staff to perform the chromocolonoscopy (£26·15 per procedure) and 
additional implementation costs (£52·93 per procedure). When all resource use for all 
procedures conducted (index and repeat Supplementary Table S4) by each arm was compared, 
standard colonoscopy cost per procedure was £190.60 compared to £271.60 per procedure for 
the chromocolonoscopy resulting in a mean cost difference of £81 (95% CI: £69.91-£92.09). 
Examining procedures separately produced the following results: 
 Index procedures only (available cases Supplementary Table S5): mean cost difference 
between arms £87.68 (95% CI: 76.83-98.53) more expensive per procedure than standard 
colonoscopy; 
 Repeat procedures only (available cases Supplementary Table S6): mean cost difference 
between arms £49.11 (95% CI: 11.33-86.88)   
 
Discussion 
Within the lack of reduction in mortality from proximal colon cancer with screening, an 
intervention that improves detection of proximal serrated lesions must be feasible within a 
screening programme and the proportion of significant proximal precursor lesions detected 
must be of the order that might affect surveillance and outcomes in the longer term. This study 
demonstrates the feasibility of recruitment of patients (82% of those eligible) and 
colonoscopists to a trial of standard versus chromocolonoscopy within a population based CRC 
screening programme. Although the procedure time took approximately 6 minutes longer in 
the chromocolonoscopy arm, we can be 95% confident that using chromocolonoscopy does not 
increase the mean time by more than 10 minutes.  The dye is safe and consequent polyp 
detection and resection is associated with a very low rate of post-polypectomy bleeding, similar 
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to the standard arm. The chromocolonoscopy arm demonstrated higher detection rates for 
proximal serrated lesions, all serrated lesions and proximal sessile serrated lesions, and there 
was more advanced neoplasia and significant serrated lesions in this arm. Colonoscopy 
performance and technical quality indicators and patient comfort scores were similar in each 
trial arm whilst the additional costs of adopting the chromocolonoscopy technique would be 
£81 per procedure. More follow up work is required to assess the extent of further costs 
involved in screening surveillance as a result of improved detection.  
 
Our study identified a number of other interesting findings. First, while dysplasia in distal SSLs 
only occurred in lesions ≥10mm, all proximal SSLs with dysplasia were smaller than this.  This 
is consistent with another recent study that found the majority of proximal dysplastic SSLs to 
be <10mm25 and suggests the need for caution in setting guidelines for clinical significance 
based solely on the size of serrated polyps. Second, in the chromocolonoscopy arm (but not the 
standard arm), advanced adenomas (of conventional type) were more common in individuals 
harbouring SSLs. The reasons for this are unclear but the improved identification of otherwise 
occult SLs by chromocolonoscopy may go some way in explaining the appearance of post-
colonoscopy interval cancers in conventional screening programmes. Thirdly, there was 
evidence that aspirin protects against advanced neoplasia. 
 
There is a perception that chromocolonoscopy is time consuming and this study provides 
quantification of the additional time taken per procedure and of the additional costs associated 
with chromocolonoscopy. The cost-consequence analysis provides an indication of the 
additional resources required to adopt this technique and shows that additional costs are 
primarily due to implementation. Some screening colonoscopists are already familiar with the 
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concept of chromocolonoscopy from their inflammatory bowel disease surveillance procedures 
and will consequently have less training requirements.26  
 
Strengths  
With 20/23 colonoscopists from 12/14 screening centres in the BSW programme participating 
in the current study, we demonstrate the feasibility and results from a real world programme-
wide roll out of chromocolonoscopy. By contrast, previous studies have largely focused on 
expert centres and expert colonoscopists.27  
 
Previous estimates of prevalence of SLs have demonstrated significant variation possibly partly 
due to inconsistency in histopathological categorisation of these lesions.13,20,28 In order to 
address this, unlike the previous RCTs involving chromocolonoscopy, this study included an 
expert GI central pathology panel reviewing all slides of proximal colonic polyps.22 
Randomisation was stratified by centre to ensure that any centre effects were balanced across 
trial arms. We demonstrated very little difference between arms in technical factors affecting 
mucosal visualization and consequent polyp detection and addressed most major sources of 
bias in previous studies due to procedure quality. To our knowledge this study is also the first 
to estimate the resource utilization associated with training and implementation of this 
intervention in routine clinical practice. 
 
Limitations 
It is difficult to completely remove bias in chromocolonoscopy as it is impossible to blind 
assessors. Withdrawal times in both groups, even where polyp resection was not required, were 
higher than the pre-specified minimum withdrawal time of 7 minutes in the quality assurance 
criteria for BSW. Previous studies suggest that longer withdrawal times may improve detection 
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rates for serrated polyps.14,29 It may be that the dye promotes longer withdrawal times which 
in turn led to the higher detection rates. However, none of the previous studies suggest that a 
withdrawal time greater than 11 minutes would be effective in independently achieving a 
significant improvement in detection rates for both adenomas as well as serrated lesions 
supporting our findings of an independent and significant positive effect of the 
chromoendoscopy.30 We did not specify the use of high definition colonoscopes as a pre-
requisite but data from previous studies suggests that this would be unlikely to influence the 
results of this study.31,32 Aspirin use was only collected for a subset of patients and the results 
should be treated with caution, especially in this selected screening population, although 
sensitivity analysis in that subset supported the main finding of the study in proximal serrated 
polyp detection rate. This was a feasibility study not powered to find differences in detection 
rates and a definitive trial with longer follow up and high definition colonoscopy mandated in 
both arms is planned. Finally, some variables were subject to recall bias e.g. smoking and 
family history of cancer/polyps. 
 
Conclusion 
It is safe and feasible to use index chromocolonoscopy within the CRC screening setting with 
an acceptable increase in procedure time of approximately 6 minutes. It is also feasible (in 
terms of safety, recruitment rates, procedure time, and trial logistics) to conduct a larger 
individually randomised trial comparing chromocolonoscopy to standard white light 
colonoscopy. Such a trial could be powered to find a difference in significant SSL detection 
rate at index since a study powered to detect a difference in PCCRC would require tens of 
thousands of paarticipants. The higher proximal serrated polyp detection rates and advanced 
neoplasia found on chromocolonoscopy in this study contribute data to the discussion around 
its impact on colonoscopy quality and PCCRC. 
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Figure 1. CONSORT diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=1031) 
Excluded (n=191) 
Ineligible (n=122) 
 Non-participating colonoscopist (n=55) 
 Colonoscopy elsewhere (n=35) 
 Surveillance (n=18) 
 Previous bowel surgery (n=9) 
 Comorbidities/unwell (n=5) 
Eligible (n=69) 
 Not interested (n=23) 
 Declined colonoscopy (n=19) 
 Worried about possible allergy/side effects (n=7) 
 Worried about possible extra time (n=3) 
 Too anxious (n=3) 
 Unable to understand (n=2) 
 Unknown reason (n=12) 
  
 
 
 
 
 
 
Allocated to standard colonoscopy (n=416) 
 
 
Randomised (n=840) 
Excluded (n=56) 
Ineligible (n=2) 
 Previous bowel surgery not mentioned previously  (n=1) 
 Comorbidities/unwell (n=1) 
Eligible (n=54) 
 Not interested (n=24) 
 Too anxious (n=7) 
 Declined/cancelled/did not attend colonoscopy(n=5) 
 Worried about possible extra time (n=4) 
 Worried about possible allergy/side effects (n=1) 
 Unknown reason (n=13) 
Consented and eligible (n=360 (87%)) 
 
 
Allocated to chromocolonoscopy (n=424) 
Excluded (n=43) 
Ineligible (n=4) 
 Previous bowel surgery not mentioned previously (n=2) 
 Comorbidities/unwell (n=2) 
Eligible (n=39) 
 Not interested (n=19) 
 Too anxious (n=4) 
 Declined/cancelled/did not attend colonoscopy(n=1) 
 Worried about possible extra time (n=3) 
 Worried about possible allergy/side effects (n=1) 
 Unknown reason (n=11) 
Consented and eligible (n=381 (90%)) 
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Figure 2. Flow diagram for key polyp detection rates by trial arm (ORs are given with 95% CIs with standard as the reference arm) 
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Anywhere 
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Table 1. Baseline Demographics 
  
Standard colonoscopy Chromocolonoscopy 
N=360  N=381 
Current smoking status     
Smoker 37 (10.3%) 45 (11.8%) 
Ex-smoker 180 (50.0%) 196 (51.4%) 
Never smoker 143 (39.7%) 139 (36.5%) 
Missing 0 (0.0%) 1 (0.3%) 
Pack years for smoker/ex-smoker – median (IQR, n, missing) 20 (10-39, 205 ,12) 16 (8-34, 231, 10) 
Family history of bowel cancer 
  
No 302 (83.9%) 318 (83.5%) 
Second degree 9 (2.5%) 13 (3.4%) 
First degree 45 (12.5%) 48 (12.6%) 
Both 3 (0.8%) 0 (0.0%) 
Missing 1 (0.3%) 2 (0.5%) 
Family history of bowel polyps 
  
No 340 (94.4%) 349 (91.6%) 
Second degree 2 (0.6%) 2 (0.5%) 
First degree 15 (4.2%) 29 (7.65) 
Missing 3 (0.8%) 1 (0.3%) 
Previous abdominal/pelvic surgery 96 (26.7%) 108 (28.3%) 
Missing 5 (1.4%) 4 (1.0%) 
Presence of diverticular disease 201 (55.8%) 195 (51.2%) 
Missing 6 (1.7%) 5 (1.3%) 
BMI – mean (SD); Obese ≥30 - n (%)  28.8 (5.1); 134 (37.2) 28.9 (5.6); 128 (33.6) 
Missing 2 (0.6%) 5 (1.3%) 
Age - median (IQR) 67.6 (62.6-70.7) 67.7 (62.7-70.8) 
Sex   
  
Male 234 (65.0%) 256 (67.2%) 
Female 126 (35.0%) 125 (32.8%) 
Aspirin data was only collected after the first 210 patients  
  N=254 N=277 
Does the patient take daily aspirin?     
Currently 52 (20.5%) 57 (20.6%) 
Previously 21 (8.3%) 24 (8.7%) 
Never 181 (71.3%) 196 (70.8%) 
If currently taking aspirin, what is daily dose?   
75mg 49/52 (94.2%) 55/57 (96.5%) 
>75mg 3/52 (5.8%) 1/57 (1.8%) 
Missing 0/57 (0.0%) 1/57 (1.8%) 
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Table 2. Index colonoscopy and associated polyp clearance procedures up to one year 
later (surveillance procedures not included) 
  Standard colonoscopy Chromocolonoscopy 
Number of participants 360 381 
Number of procedures   
Total number  427 477 
Per person rate 1.19 1.25 
Number of people receiving >1 procedure 53 (14.7%) 65 (17.1%) 
Nature of procedure   
Index 360 381 
Repeat to check completeness of polyp resection 26 33 
Repeat due to incomplete previous procedure 2 0 
Repeat due to poor bowel preparation at previous procedure 11 8 
Repeat for therapeutic indication 28 55 
Type of procedure   
Colonoscopy 399 430 
Flexible sigmoidoscopyA 28 47 
Final outcome   
Repeat  21 (5.8%) 20 (5.2%) 
Discharge back to routine FOBT screening 162 (45.0%) 159 (41.7%) 
No further colonoscopies required due to age limit/other bowel condition  22 (6.1%) 19 (5.0%) 
3 year surveillance – intermediate risk 64 (17.8%) 63 (16.5%) 
12 month surveillance – high risk  48 (13.3%) 76 (19.9%) 
Refer to surgery for non-cancer indication 2 (0.6%) 4 (1.0%) 
CancerB 41 (11.4%) 40 (10.5%) 
Inadequate bowel preparation at index then no further colonoscopies 2 (0.6%) 3 (0.8%) 
First colonoscopy with adequate bowel preparation   
Number of participants 358 378 
Bowel preparation score   
Adequate 237 (66.2%) 240 (63.5%) 
Excellent 120 (33.5%) 135 (35.7%) 
Missing 1 (0.3%) 3 (0.8%) 
Completion rate   
Complete (caecum/ileum) 345 (96.4%) 366 (96.8%) 
Incomplete (other) 13 (3.6%) 12 (3.2%) 
Average procedure time (minutes) – mean (SD); median (IQR) 30.6 (13.7); 28 (22-36) 36.8 (15.0); 34 (27-45) 
Missing 0 (0.0%) 1 (0.3%) 
When polyps removed – mean (SD); median (IQR); n 35.2 (14.2); 33 (25-42); 207 41.3 (15.2); 39 (30-50); 244 
When no polyps removed – mean (SD); median (IQR; n 24.2 (9.8); 24 (17-28); 151 28.6 (10.5); 28 (21-34); 133 
When endoscopist assessed procedure as difficult – mean (SD); median (IQR; n 41.4 (14.8); 40 (31-48); 58 47.4 (15.9); 44 (36-58); 66 
Average withdrawal time (minutes) – mean (SD); median (IQR)C 18.7 (11.3); 16 (11-22) 24.1 (12.7); 21 (15-31) 
Missing 0 (0.0%) 1 (0.3%) 
When polyps removed – mean (SD); median (IQR); n 23.0 (12.2); 20 (15-28); 204 28.5 (12.8); 25.5 (19-35); 242 
When no polyps removed – mean (SD); median (IQR; n 12.5 (5.6); 11 (8-16); 141 15.4 (6.6); 15 (10-18); 123 
Endoscopist assessment of procedural difficulty   
Easy 108 (30.2%) 106 (28.0%) 
Average 172 (48.0%) 190 (50.3%) 
Difficult 58 (16.2%) 66 (17.5) 
Unable to complete 13 (3.6%) 12 (3.2%) 
Missing 7 (2.0%) 4 (1.1%) 
Procedure comfort score (Gloucester)    
1 73 (20.4%) 72 (19.0%) 
2 158 (44.1%) 180 (47.6%) 
3 107 (29.9%) 101 (26.7%) 
4 17 (4.7%) 23 (6.1%) 
5 2 (0.6%) 2 (0.5%) 
Missing 1 (0.3%) 0 (0.0%) 
AAll repeats; BIn each arm, one found at first repeat, all others at index; COnly recorded for complete procedures 
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Table 3. Polyps (WHO classification) retrieved over first and repeat procedures  
 
  Standard colonoscopy (N=360) Chromocolonoscopy (N=381) 
  Number of participants % Number of participants % 
No polyps or cancer 116 32.2 98 25.7 
Cancers 41 11.4 40 10.5 
Proximal 33 9.2 26 6.8 
Distal 8 2.2 14 3.7 
  Number of polyps Polyp detection rate Number of polyps Polyp detection rate 
  n per patient n % n per patient n % 
Polyps (any) 570 1.583 217 60.3 903 2.370 258 67.7 
Adenomas 482 1.339 203 56.4 734 1.927 232 60.9 
1. HGD or villous features 36 0.100 33 9.2 39 0.102 34 8.9 
2. Other 446 1.239 193 53.6 695 1.824 220 57.7 
a. Other ≥ 10mm 122 0.339 85 23.6 152 0.399 105 27.6 
Serrated lesions (SL)  78 0.217 51 14.2 141 0.370 81 21.3 
1. Any SSL 24 0.067 21 5.8 61 0.160 34 8.9 
a. SSL no dysplasia 20 0.056 17 4.7 55 0.144 31 8.1 
ai. SSL no dysplasia ≥ 10mm 2 0.006 2 0.6 11 0.029 8 2.1 
b. SSL with dysplasia 4 0.011 4 1.1 6 0.016 5 1.3 
bi. SSL with dysplasia ≥ 10mm 2 0.006 2 0.6 4 0.010 3 0.8 
2. TSA 1 0.003 1 0.3 5 0.013 5 1.3 
3. HP 53 0.147 37 10.3 75 0.197 54 14.2 
Other 8 0.022 8 2.2 27 0.071 21 5.5 
1. Mixed polyp A 2 0.006 2 0.6 4 0.010 4 1.0 
2. Inflammatory 3 0.008 3 0.8 14 0.037 11 2.9 
3. Dysplasia and  inflammation 0 0.000 0 0.0 3 0.008 1 0.3 
4 .Unclassifiable 3 0.008 3 0.8 6 0.016 6 1.6 
Proximal SLs 28 0.078 23 6.4 60 0.157 45 11.8 
1. Any SSL 18 0.050 16 4.4 39 0.102 30 7.9 
a.. SSL no dysplasia 16 0.044 14 3.9 37 0.097 28 7.3 
ai. SSL no dysplasia ≥ 10mm 1 0.003 1 0.3 9 0.024 7 1.8 
b. SSL with dysplasia 2 0.006 2 0.6 2 0.005 2 0.5 
bi. SSL with dysplasia ≥ 10mm 0 0.000 0 0.5 0 0.000 0 0.0 
2. TSA 0 0.000 0 0.0 1 0.003 1 0.3 
3. HP 10 0.028 9 2.5 20 0.052 19 5.0 
“Advanced neoplasia” B         
Overall 164 0.456 114 31.7 214 0.562 136 35.7 
Proximal 45 0.125 33 9.2 57 0.150 32 8.4 
“Advanced adenomas” C         
Overall 156 0.433 109 30.3 190 0.499 128 33.6 
Proximal 42 0.117 30 8.3 43 0.113 27 7.1 
“Significant SLs” D         
Overall 7 0.019 7 1.9 22 0.058 16 4.2 
Proximal 3 0.008 3 0.8 12 0.031 9 2.4 
At least one SL and adenoma         
Overall   39 10.8   61 16.0 
Proximal   13 3.6   28 7.3 
AOne polyp in standard arm was advanced, two in chromo colonoscopy arm were advanced 
BAdvanced adenoma or “Significant SL” or advanced mixed polyp 
CHGD or villous features or ≥10mm  
DSSL with dysplasia or any SSL≥10mm or TSA  
 
